Doxycycline for Helicobacter Pylori Rescue Treatment
Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · May 16, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment option for people who have a Helicobacter pylori (H. pylori) infection that has not responded to previous treatments. H. pylori is a type of bacteria that can cause stomach problems, and the current recommended treatment includes a combination of medications. However, one of these medications, tetracycline, is not available in China, and the standard treatment can cause side effects that make it hard for some patients to stick with it. In this trial, researchers are testing whether replacing tetracycline with doxycycline in a 14-day treatment plan still works effectively and is easier for patients to tolerate.
To be eligible for this study, participants need to be between 18 and 80 years old, have a confirmed H. pylori infection, and have previously tried and failed treatment for it. Participants will be asked to sign consent to take part in the study. Those who have not been treated for H. pylori before or have certain health conditions, like severe diseases or a history of stomach surgery, will not be able to join. If you choose to participate, you can expect close monitoring and support from the research team throughout the trial. This study is currently looking for participants, and your involvement could help improve treatment options for others with H. pylori infections in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability and willingness to participate in the study and to sign and give informed consent
- • Confirmed H. pylori infection and with previous treatment failure
- Exclusion Criteria:
- • subjects naive to H. pylori treatment,
- • under 18 or over 80 years old
- • history of gastrectomy
- • pregnant or lactating women
- • severe systemic diseases or malignancy
- • administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
About Shanghai Jiao Tong University School Of Medicine
Shanghai Jiao Tong University School of Medicine is a leading academic institution in China, renowned for its commitment to advancing medical research and education. As a prominent clinical trial sponsor, the school leverages its extensive expertise in biomedical sciences and innovative healthcare solutions to conduct rigorous clinical studies aimed at improving patient outcomes. With a focus on collaboration and translational research, the institution fosters partnerships with healthcare providers, industry leaders, and regulatory bodies to ensure the highest standards of scientific integrity and ethical conduct in clinical trials. Through its research initiatives, Shanghai Jiao Tong University School of Medicine strives to contribute significantly to the global medical community and enhance the quality of healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported